Affimed N.V.

Affimed N.V. is a clinical-stage biopharmaceutical company developing cancer immunotherapies. Lead product candidates include AFM13 for CD30-positive lymphoma, AFM24 for advanced cancers, and AFM28 for acute myeloid leukemia. AFM32 is another ICE candidate in preclinical development for solid tumors. The company has collaborations with Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

0.2 USD

Potential

-100%

Strengths

Price to book ratio (0.01) is lower than the sector mean (24.44).
EV/EBITDA (0.25) is lower than the sector mean (85.60).
EV/EBIT (0.25) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	0.2
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.3